Open in interactive viewer → charts, metric popovers & call review

Solesence Turns the Corner — and Quietly Lowers the Bar

A record Q3, a 1,550-basis-point gross-margin jump, a stock up ~69% in four sessions — and a management team that trimmed EBITDA guidance and pushed its long-promised investor deck into 2027.
SLSN · Earnings Call · 2026-11-12

The quarter nobody modeled

Solesence has spent two years apologizing for its factory. On Thursday it stopped. Q3 2026 revenue came in at $20.2M, up 38% from $14.6M, the best third quarter in company history. “Gross margin for the third quarter increased by 1,550 basis points to 39.3%, compared to 23.8% in Q3 of 2025” — Laura Riffner, Chief Financial Officer · 2026-11-12, and net income swung to a record $3.7M from a $1M loss. The mechanism was refreshingly physical: overall equipment effectiveness across all production lines went from 40% to 55% in twelve months, direct labor fell by more than $2M year-to-date, and indirect labor by another $400K. That is a different company than the one in the fundamentals file. The last filed quarter — Q2 2026 — showed $15M of revenue at a 31.0% gross margin, essentially breakeven. The step change is real, but it is one quarter old and, as yet, unfiled. Kevin Cureton's framing of what happened is the single best line of the call: “we have figuratively crossed the chasm, where the level of these expenses will increase at a rate substantially below the growth rate of our top line” — Kevin Cureton, President and Chief Executive Officer · 2026-11-12. That is the whole thesis in one sentence — from here, incremental revenue should cost less than the last dollar of revenue did.

The guidance that refused to move

The problem is that the numbers and the words point in opposite directions. Analysts asked, twice, why a 38% growth quarter with record profit did not produce a raise. Cureton's answer was candour of a sort: “We've tried to be as consistent and somewhat conservative in the guidance that we provide” — Kevin Cureton, President and Chief Executive Officer · 2026-11-12. The arithmetic actually supports him — management reiterated at least $65M of shipped and on-hand orders for the year, and with roughly $48M booked through three quarters, that implies Q4 of about $17M, up ~36% year over year but sequentially down from Q3. The trouble is elsewhere. Buried three sentences into the answer, the CFO confirmed the other shoe: “It's the EBITDA guidance that we did. We're no longer guiding towards double-digit growth this year.” — Laura Riffner, Chief Financial Officer · 2026-11-12 Full-year EBITDA margins will land "slightly below" the previously communicated double-digit target. That is a guidance cut delivered inside a record quarter, blamed on a soft first half. And it directly reverses a promise made in March, when the CFO said the company was “targeting an increase in EBITDA to return to double-digit numbers in 2026” — Laura Riffner, CFO · 2026-03-31. Nine months later, double digits are being deferred into a "greater than 20% EBITDA" ambition that Cureton now attaches to 2027 and beyond.

as you look out into 2027, is this quarter the one that you build upon, or was this kind of an anomaly with respect to sales and margins? ... can we expect these sorts of margins and these sorts of sales levels which would bring you back to the growth you were at a couple of years ago, or again, was this kind of a fluke?

Unknown Analyst, Analyst · 2026-11-12
The keyword the transcript machinery pulled from that exchange — anomaly with respect — is the right one. The CFO's answer was emphatic ("I do not think, and we do not think, that it is a fluke"), but the CEO immediately walked it back in time: “we expect to grow, certainly in 2027, but we think that greater growth is in 2028 than it is in 2027” — Kevin Cureton, President and Chief Executive Officer · 2026-11-12. A company that just printed 38% growth is telling you the real acceleration is two years away. That is either admirable honesty from a $64M microcap or a tell that the Q3 comp was flattered by a mix shift toward larger brand partners.

What management stopped saying

The company-specific keyword rotation is the most informative thing in this report. For five straight quarters the language was defensive: inventory control ranked near the top of the deck in Q2 2026, Q1 2026 and twice in 2025; production efficiency was the number-one company keyword last quarter; a costing-methodology issue forced a restatement. This quarter those terms fall away entirely and are replaced by labor efficiency, indirect COGS, fixed costs, and the implementation phase of lean management. The vocabulary moved from diagnosis to arithmetic. The restatement itself — a genuine de-risking event — got one sentence from the CFO and no questions. Two genuinely new threads appeared. First, customer concentration, which surfaced for the first time in the company's keyword history because an analyst asked directly. Cureton's reply — “We've had some pretty fabulous growth with some of our larger customers” — Kevin Cureton, President and Chief Executive Officer · 2026-11-12 — is good news and risk in the same breath, and his remedy (selective globalization, more brand partners) is a 2027-2028 answer to a 2026 question. Second, BEMT. Last quarter the newly FDA-approved UV filter was a Q&A curiosity — “I think the FDA approved a non-mineral-based sunscreen platform recently. Are you seeing any changes in interest in your mineral-based sunscreen technology?” — James Liberman, Analyst · 2026-08-19 This quarter it is a prepared-remarks pillar, complete with concept formulas with BEMT already shown to key brand partners and product potentially on shelf in 2027. That is the correct sequencing — a curiosity promoted to a strategy — though note it is the third consecutive call on which a catalyst has been dated "next year." Which brings up the oldest unresolved item. In November 2025, Cureton said “we do plan on presenting our first investor presentation, Tony” — Kevin Carrington, CEO · 2025-11-11. In March it was "in the months to come." On Thursday it became: “It is our intent to first and foremost get the long-awaited investor presentation completed” — Kevin Cureton, President and Chief Executive Officer · 2026-11-12 — with conferences now scheduled for 2027. A twelve-month slip on a slide deck is a governance signal in a stock this small.

The tape is voting on the quarter, not the year

The market's reaction has been violent and narrow. SLSN is up roughly 67% over ninety days, and essentially all of it arrived in the last four sessions — a ~69% vertical move in the days around this print. Set against a 70.8% drawdown from the June 2025 peak of $5.21, this is a broken stock snapping, not a re-rating. At 0.9x trailing revenue, down roughly 80% year over year, even a modest restoration of confidence in the numbers moves the equity a long way; the same is true in reverse. And the balance sheet has not yet caught up with the P&L. Effective net cash sits at roughly negative $3M, and receivables are 61% of revenue, up 6.7 points. Growth of this kind consumes cash before it produces it. Finally, a contrast worth holding onto. Among consumer names reporting in the same window, the vocabulary is defensive and external — FOSL talking about the next price point, ONON booking a tariff refund, Sally Beauty grinding out comp sales; globally, tariff refund was the single hottest market keyword of the prior quarter. Solesence said the word "tariff" zero times, despite having fielded a China-packaging question as recently as May 2025. Its story is entirely internal: a factory that finally works. That is a good story, and Q3 is the first hard evidence for it. But read the whole call and a subtler shape emerges — the gross margin is inflecting while the guidance is flattening, the near-term EBITDA target has been pushed out, the investor pitch has slipped another year, and the CEO has already told you that the best growth is in 2028. The chasm, if crossed, is behind them; the proof that they have stopped apologizing for it is not yet in a 10-Q.